Mechanistically, TP-TR downregulated the TLR4/TGF-β level to alleviate airway inflammation and pulmonary fibrosis, concurrently inhibiting MMP9/12 and MUC5AC/5B expression, thereby delaying lung tissue destruction and reducing mucus production. Here, MMP9 is linked to pulmonary fibrosis.